Suppr超能文献

慢性淋巴细胞白血病中IgM和IgD信号传导的功能差异

Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.

作者信息

Ten Hacken Elisa, Sivina Mariela, Kim Ekaterina, O'Brien Susan, Wierda William G, Ferrajoli Alessandra, Estrov Zeev, Keating Michael J, Oellerich Thomas, Scielzo Cristina, Ghia Paolo, Caligaris-Cappio Federico, Burger Jan A

机构信息

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77230;

Department of Medicine II, Hematology/Oncology, Goethe University, 60590 Frankfurt, Germany; and.

出版信息

J Immunol. 2016 Sep 15;197(6):2522-31. doi: 10.4049/jimmunol.1600915. Epub 2016 Aug 17.

Abstract

BCR signaling is a central pathogenetic pathway in chronic lymphocytic leukemia (CLL). Most CLL cells express BCRs of IgM and IgD isotypes, but the contribution of these isotypes to functional responses remains incompletely defined. We therefore investigated differences between IgM and IgD signaling in freshly isolated peripheral blood CLL cells and in CLL cells cultured with nurselike cells, a model that mimics the lymph node microenvironment. IgM signaling induced prolonged activation of ERK kinases and promoted CLL cell survival, CCL3 and CCL4 chemokine secretion, and downregulation of BCL6, the transcriptional repressor of CCL3 In contrast, IgD signaling induced activation of the cytoskeletal protein HS1, along with F-actin polymerization, which resulted in rapid receptor internalization and failure to support downstream responses, including CLL cell survival and chemokine secretion. IgM and IgD receptor downmodulation, HS1 and ERK activation, chemokine secretion, and BCL6 downregulation were also observed when CLL cells were cocultured with nurselike cells. The Bruton's tyrosine kinase inhibitor ibrutinib effectively inhibited both IgM and IgD isotype signaling. In conclusion, through a variety of functional readouts, we demonstrate very distinct outcomes of IgM and IgD isotype activation in CLL cells, providing novel insight into the regulation of BCR signaling in CLL.

摘要

BCR信号通路是慢性淋巴细胞白血病(CLL)的核心致病途径。大多数CLL细胞表达IgM和IgD同种型的BCR,但这些同种型对功能反应的贡献仍未完全明确。因此,我们研究了新鲜分离的外周血CLL细胞以及与类滋养细胞共培养的CLL细胞(一种模拟淋巴结微环境的模型)中IgM和IgD信号的差异。IgM信号诱导ERK激酶的长期激活,并促进CLL细胞存活、CCL3和CCL4趋化因子分泌以及BCL6的下调,BCL6是CCL3的转录抑制因子。相比之下,IgD信号诱导细胞骨架蛋白HS1的激活以及F-肌动蛋白聚合,导致受体快速内化且无法支持包括CLL细胞存活和趋化因子分泌在内的下游反应。当CLL细胞与类滋养细胞共培养时,也观察到了IgM和IgD受体下调、HS1和ERK激活、趋化因子分泌以及BCL6下调。布鲁顿酪氨酸激酶抑制剂依鲁替尼有效地抑制了IgM和IgD同种型信号。总之,通过各种功能读数,我们证明了CLL细胞中IgM和IgD同种型激活的非常不同的结果,为CLL中BCR信号通路的调节提供了新的见解。

相似文献

1
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.
J Immunol. 2016 Sep 15;197(6):2522-31. doi: 10.4049/jimmunol.1600915. Epub 2016 Aug 17.
2
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
Leukemia. 2019 Feb;33(2):287-298. doi: 10.1038/s41375-018-0303-x. Epub 2018 Dec 16.
3
BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia.
Ann Hematol. 2016 Dec;95(12):1979-1988. doi: 10.1007/s00277-016-2788-6. Epub 2016 Aug 20.
7
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
Blood. 2005 Jun 15;105(12):4820-7. doi: 10.1182/blood-2004-07-2669. Epub 2005 Feb 22.
10
Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.
Blood. 2014 Nov 13;124(20):3101-9. doi: 10.1182/blood-2014-04-567198. Epub 2014 Aug 28.

引用本文的文献

1
Dynamic stimulation promotes functional tissue-like organization of a 3D human lymphoid microenvironment model in vitro.
Cell Rep Methods. 2025 Jul 21;5(7):101105. doi: 10.1016/j.crmeth.2025.101105. Epub 2025 Jul 11.
3
Targeted small molecule therapy and inhibitors for lymphoma.
Future Med Chem. 2024;16(14):1465-1484. doi: 10.1080/17568919.2024.2359893. Epub 2024 Jul 17.
4
The malignant transformation potential of the oncogene STYK1/NOK at early lymphocyte development in transgenic mice.
Biochem Biophys Rep. 2024 Apr 12;38:101709. doi: 10.1016/j.bbrep.2024.101709. eCollection 2024 Jul.
7
Chronic Lymphocytic Leukemia: Disease Biology.
Acta Haematol. 2024;147(1):8-21. doi: 10.1159/000533610. Epub 2023 Sep 16.
8
Hyper-IgD Syndrome: Caused by Deficiency on Ras Prenylation and Trained Immunity?
J Clin Immunol. 2023 Nov;43(8):1740-1742. doi: 10.1007/s10875-023-01548-x. Epub 2023 Jul 7.

本文引用的文献

2
Molecular Mechanisms of B Cell Antigen Gathering and Endocytosis.
Curr Top Microbiol Immunol. 2016;393:45-63. doi: 10.1007/82_2015_476.
3
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
Biochim Biophys Acta. 2016 Mar;1863(3):401-413. doi: 10.1016/j.bbamcr.2015.07.009. Epub 2015 Jul 17.
5
Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.
Clin Cancer Res. 2015 Oct 15;21(20):4642-51. doi: 10.1158/1078-0432.CCR-15-0781. Epub 2015 Jun 18.
6
Responsiveness of B cells is regulated by the hinge region of IgD.
Nat Immunol. 2015 May;16(5):534-43. doi: 10.1038/ni.3141. Epub 2015 Apr 6.
8
Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.
Blood. 2015 Mar 5;125(10):1578-88. doi: 10.1182/blood-2014-07-587790. Epub 2015 Jan 6.
9
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Lancet Oncol. 2014 Sep;15(10):1090-9. doi: 10.1016/S1470-2045(14)70335-3. Epub 2014 Aug 20.
10
The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia.
Semin Hematol. 2014 Jul;51(3):158-67. doi: 10.1053/j.seminhematol.2014.05.003. Epub 2014 May 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验